FDA OKs PD-1 Inhibitor for Adjuvant Treatment of Kidney Cancer
The FDA approved pembrolizumab (Keytruda) for the adjuvant treatment of renal cell carcinoma (RCC) for patients who have an intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions, the agency announced. Approval was based on results from the KEYNOTE-564 trial, which demonstrated that adjuvant pembrolizumab following nephrectomy significantly […]
Immunotherapy Combo in Advanced RCC Led to More Time Off Treatment
Nearly one-fifth of patients with intermediate- or poor-risk advanced renal cell carcinoma (RCC) treated with nivolumab (Opdivo) plus ipilimumab (Yervoy) in the CheckMate 214 trial were alive and treatment free beyond 3 years. Among the phase III trial participants, the treatment-free survival (TFS) rate at 42 months was 18% for those who were randomized to […]
Nonsteroidal MRA Drug Cuts Risks in Earlier Diabetic Kidney Disease
Finerenone (Kerendia) prevents cardiovascular (CV) and some renal events in type 2 diabetes patients with earlier stages of kidney disease, the FIGARO-DKD trial showed. In the trial’s stage 1 to 4 kidney disease patients with moderate-to-severe albuminuria, the nonsteroidal mineralocorticoid receptor antagonist (MRA) reduced the composite of CV death, nonfatal myocardial infarction or stroke, or […]
More Data Support Active Surveillance for Small Renal Masses
Patients with small renal masses avoided interventions in 70% of cases during about 3 years of active surveillance that had a standard protocol to identify progression requiring intervention, investigators reported. During 31-34 months of follow-up, 37 of 123 patients met criteria for intervention, and 29 of the 37 underwent delayed intervention. The cohort had a […]